Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 398

1.

Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F.

Circulation. 2000 Aug 22;102(8):858-64.

3.

Clinical course of hypertrophic cardiomyopathy with survival to advanced age.

Maron BJ, Casey SA, Hauser RG, Aeppli DM.

J Am Coll Cardiol. 2003 Sep 3;42(5):882-8.

4.

Hypertrophic cardiomyopathy: risk factors for life and living benefits insurance.

Pokorski RJ.

J Insur Med. 2002;34(1):43-60. Review.

PMID:
15303593
5.

Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy.

Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ.

J Am Coll Cardiol. 2005 Mar 1;45(5):697-704.

6.

Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.

Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ.

Circulation. 2001 Nov 20;104(21):2517-24.

7.

Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.

Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, Gates C, Jefferies JL, Kim JJ, Price JF, Dreyer WJ, Towbin JA, Denfield SW.

J Am Coll Cardiol. 2009 Jul 14;54(3):250-4. doi: 10.1016/j.jacc.2009.03.051.

8.

Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death.

Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ.

Eur Heart J. 2009 Jul;30(13):1627-34. doi: 10.1093/eurheartj/ehp121.

PMID:
19406869
9.
10.

Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.

Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ.

J Am Coll Cardiol. 1995 Nov 15;26(6):1529-36.

11.

[Evaluation of the risk of sudden death in hypertrophic cardiomyopathy].

Sadoul N, de Chillou C, Aliot E, McKenna WJ.

Arch Mal Coeur Vaiss. 1999 Apr;92 Spec No 1:65-73. Review. French.

PMID:
10326160
12.

Sudden death in hypertrophic and dilated cardiomyopathy.

Koga Y, Ogata M, Kihara K, Tsubaki K, Toshima H.

Jpn Circ J. 1989 Dec;53(12):1546-56.

PMID:
2632825
13.

Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.

Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS.

Circulation. 2013 Feb 5;127(5):585-93. doi: 10.1161/CIRCULATIONAHA.112.136085.

14.

Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities.

Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF.

J Am Coll Cardiol. 1999 May;33(6):1590-5.

15.

Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.

Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.

J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35. doi: 10.1016/j.jacc.2013.01.037.

16.

Left ventricular remodeling of hypertrophic cardiomyopathy: longitudinal observation in rural community.

Kitaoka H, Kubo T, Okawa M, Hitomi N, Furuno T, Doi YL.

Circ J. 2006 Dec;70(12):1543-9.

17.

Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy.

Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, Sherrid MV.

J Am Coll Cardiol. 2003 Mar 19;41(6):974-80.

18.

[Interventional treatment in hypertrophic cardiomyopathy].

Gietzen FH, Schümmelfeder J, Neuser H, Brunn J, Schumacher B, Kerber S.

Herz. 2005 Mar;30(2):102-10. Review. German.

PMID:
15875098
19.

Management of hypertrophic cardiomyopathy in children.

Seggewiss H, Rigopoulos A.

Paediatr Drugs. 2003;5(10):663-72. Review.

PMID:
14510624
20.

Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L.

Pacing Clin Electrophysiol. 2003 Sep;26(9):1887-96.

PMID:
12930505

Supplemental Content

Support Center